tiprankstipranks
ANI Pharmaceuticals Inc (DE:BSFA)
STUTTGART:BSFA
Germany Market
BSFA
ANI Pharmaceuticals
RESEARCH TOOLSreports

ANI Pharmaceuticals (BSFA) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

BSFA Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
Based on 6 analysts giving stock ratings to
ANI
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BSFA Stock 12 Month Forecast

Average Price Target

€94.48
▲(34.02% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for ANI Pharmaceuticals in the last 3 months. The average price target is €94.48 with a high forecast of €107.48 and a low forecast of €78.88. The average price target represents a 34.02% change from the last price of €70.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"53":"€53","108":"€108","66.75":"€66.8","80.5":"€80.5","94.25":"€94.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107.48372824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€107.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.48166434000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€94.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.87918766,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€78.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[53,66.75,80.5,94.25,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.5,71.49874832615384,74.49749665230769,77.49624497846153,80.49499330461539,83.49374163076924,86.49248995692308,89.49123828307692,92.48998660923077,95.48873493538463,98.48748326153847,101.48623158769232,104.48497991384616,{"y":107.48372824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.5,70.49858956461539,72.49717912923077,74.49576869384616,76.49435825846155,78.49294782307693,80.49153738769232,82.49012695230769,84.48871651692308,86.48730608153846,88.48589564615385,90.48448521076924,92.48307477538462,{"y":94.48166434000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.5,69.29839905076923,70.09679810153847,70.89519715230769,71.69359620307692,72.49199525384616,73.29039430461539,74.08879335538461,74.88719240615384,75.68559145692308,76.48399050769231,77.28238955846153,78.08078860923077,{"y":78.87918766,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€107.48Average Price Target€94.48Lowest Price Target€78.88
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:BSFA
Gary Nachman
Canaccord Genuity
Canaccord Genuity
€78.88
Hold
11.89%
Upside
Initiated
07/17/26
ANI Pharmaceuticals initiated with a Hold at CanaccordANI Pharmaceuticals initiated with a Hold at Canaccord
Guggenheim Analyst forecast on DE:BSFA
Vamil Divan
Guggenheim
Guggenheim
€107.48
Buy
52.46%
Upside
Reiterated
07/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DE:BSFA
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€104.88
Buy
48.77%
Upside
Reiterated
07/13/26
Buy Rating Reaffirmed on Cortrophin Strength and ILUVIEN Upside; $121 Price Target Maintained
Barclays Analyst forecast on DE:BSFA
Glen Santangelo
Barclays
Barclays
€86.68
Buy
22.95%
Upside
Reiterated
05/20/26
ANI Pharmaceuticals (ANIP) Gets a Buy from Barclays
Truist Financial Analyst forecast on DE:BSFA
Les Sulewski
Truist Financial
Truist Financial
―
Hold
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Definitive Healthcare Corp (NASDAQ: DH) and Denali Therapeutics (NASDAQ: DNLI)
J.P. Morgan Analyst forecast on DE:BSFA
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
―
Buy
―
Reiterated
05/08/26
Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum
Piper Sandler Analyst forecast on DE:BSFA
David Amsellem
Piper Sandler
Piper Sandler
€96.22
Buy
36.48%
Upside
Reiterated
04/23/26
Piper Sandler Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)
Jefferies Analyst forecast on DE:BSFA
Faisal Khurshid
Jefferies
Jefferies
€104.02
Buy
47.54%
Upside
Reiterated
03/25/26
ANI Pharmaceuticals (ANIP) Receives a Rating Update from a Top Analyst
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:BSFA
Gary Nachman
Canaccord Genuity
Canaccord Genuity
€78.88
Hold
11.89%
Upside
Initiated
07/17/26
ANI Pharmaceuticals initiated with a Hold at CanaccordANI Pharmaceuticals initiated with a Hold at Canaccord
Guggenheim Analyst forecast on DE:BSFA
Vamil Divan
Guggenheim
Guggenheim
€107.48
Buy
52.46%
Upside
Reiterated
07/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DE:BSFA
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€104.88
Buy
48.77%
Upside
Reiterated
07/13/26
Buy Rating Reaffirmed on Cortrophin Strength and ILUVIEN Upside; $121 Price Target Maintained
Barclays Analyst forecast on DE:BSFA
Glen Santangelo
Barclays
Barclays
€86.68
Buy
22.95%
Upside
Reiterated
05/20/26
ANI Pharmaceuticals (ANIP) Gets a Buy from Barclays
Truist Financial Analyst forecast on DE:BSFA
Les Sulewski
Truist Financial
Truist Financial
―
Hold
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Definitive Healthcare Corp (NASDAQ: DH) and Denali Therapeutics (NASDAQ: DNLI)
J.P. Morgan Analyst forecast on DE:BSFA
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
―
Buy
―
Reiterated
05/08/26
Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum
Piper Sandler Analyst forecast on DE:BSFA
David Amsellem
Piper Sandler
Piper Sandler
€96.22
Buy
36.48%
Upside
Reiterated
04/23/26
Piper Sandler Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)
Jefferies Analyst forecast on DE:BSFA
Faisal Khurshid
Jefferies
Jefferies
€104.02
Buy
47.54%
Upside
Reiterated
03/25/26
ANI Pharmaceuticals (ANIP) Receives a Rating Update from a Top Analyst
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ANI Pharmaceuticals

3 Months
Faisal KhurshidJefferies
Success Rate
7/9 ratings generated profit
78%
Average Return
+15.36%
Copying Faisal Khurshid's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +15.36% per trade.
1 Year
Faisal KhurshidJefferies
Success Rate
8/9 ratings generated profit
89%
Average Return
+22.21%
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +22.21% per trade.
2 Years
Faisal KhurshidJefferies
Success Rate
8/9 ratings generated profit
89%
Average Return
+22.36%
Copying Faisal Khurshid's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +22.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSFA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
5
5
2
2
1
Buy
2
5
4
5
2
Hold
1
2
1
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
12
7
9
4
In the current month, BSFA has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BSFA average Analyst price target in the past 3 months is 94.48.
Each month's total comprises the sum of three months' worth of ratings.

BSFA Financial Forecast

BSFA Earnings Forecast

Next quarter’s earnings estimate for BSFA is €1.77 with a range of €1.66 to €1.97. The previous quarter’s EPS was €1.78. BSFA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BSFA has Performed in-line its overall industry.
Next quarter’s earnings estimate for BSFA is €1.77 with a range of €1.66 to €1.97. The previous quarter’s EPS was €1.78. BSFA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BSFA has Performed in-line its overall industry.

BSFA Sales Forecast

Next quarter’s sales forecast for BSFA is €225.56M with a range of €219.55M to €231.78M. The previous quarter’s sales results were €205.91M. BSFA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year BSFA has Performed in-line its overall industry.
Next quarter’s sales forecast for BSFA is €225.56M with a range of €219.55M to €231.78M. The previous quarter’s sales results were €205.91M. BSFA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year BSFA has Performed in-line its overall industry.

BSFA Stock Forecast FAQ

What is DE:BSFA’s average 12-month price target, according to analysts?
Based on analyst ratings, ANI Pharmaceuticals Inc’s 12-month average price target is 94.48.
    What is DE:BSFA’s upside potential, based on the analysts’ average price target?
    ANI Pharmaceuticals Inc has 34.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ANI Pharmaceuticals Inc a Buy, Sell or Hold?
          ANI Pharmaceuticals Inc has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
            What is ANI Pharmaceuticals Inc’s share price target?
            The average share price target for ANI Pharmaceuticals Inc is 94.48. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €107.48 ,and the lowest forecast is €78.88. The average share price target represents 34.02% Increase from the current price of €70.5.
              What do analysts say about ANI Pharmaceuticals Inc?
              ANI Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of ANI Pharmaceuticals Inc?
                To buy shares of DE:BSFA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.